Atlas Trials

A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Clinical trial NCT06143579 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06143579
Sponsor
Sun Yat-sen University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Potentially Resectable Hepatocellular Carcinoma
Start date
2023-12-15
Primary completion
2025-03-03
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.